HER2 testing in gastric cancer: An update
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer. With the recent introduction of HER2 molecular targeted therapy for patients with advanced gastric cancer, determination of HER2 status is crucial in order to select patients who may benefit from this treatment. This paper provides an update on our knowledge of HER2 in gastric and gastroesophageal cancer, including the prognostic relevance of HER2, the key differences between HER2 protein expression interpretation in breast and gastric cancer, the detection methods and the immunohistochemistry scoring system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Van Cutsem, E., Bang, Y.-J., Feng-yi, F., Xu, J. M., Lee, K.-W., Jiao, S.-C., Chong, J. L., López-Sanchez, R. I., Price, T., Gladkov, O., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-014-0402-y · Cited by 608
Advanced gastric cancer: Current treatment landscape and future perspectives
Digklia, A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2403 · Cited by 560
Rüschoff, J., Dietel, M., Baretton, G., Arbogast, S., Walch, A., Monges, G., Chenard, M.-P., Penault-Llorca, F., Nagelmeier, I., Schlake, W., et al. (2010) · Virchows Archiv · doi:10.1007/s00428-010-0952-2 · Cited by 486
HER2 expression status in diverse cancers: review of results from 37,992 patients
Yan, M., Schwaederle, M., Arguello, D., Millis, S. Z., Gatalica, Z., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9552-6 · Cited by 483
Janjigian, Y. Y., Werner, D., Pauligk, C., Steinmetz, K., Kelsen, D. P., Jäger, E., Altmannsberger, H. M., Robinson, E., Tafe, L. J., Tang, L. H., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds104 · Cited by 356
HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
Park, D. I., Yun, J. W., Park, J. H., Oh, S. J., Kim, H. J., Cho, Y. K., Sohn, C. I., Jeon, W. K., Kim, B. I., Yoo, C. H., et al. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-9057-1 · Cited by 329
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
Jørgensen, J. T., & Hersom, M. (2012) · Journal of Cancer · doi:10.7150/jca.4090 · Cited by 279
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
Grabsch, H., Sivakumar, S., Gray, S., Gabbert, H. E., & Müller, W. (2010) · Analytical Cellular Pathology · doi:10.1155/2010/519498 · Cited by 263
Kim, K. C., Koh, Y. W., Chang, H.-M., Kim, T. H., Yook, J. H., Kim, B. S., Jang, S. J., & Park, Y. S. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1695-2 · Cited by 175
HER2 Testing in Gastric Cancer
Albarello, L., Pecciarini, L., & Doglioni, C. (2011) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3182026d72 · Cited by 172
Clinical impact of tumour biology in the management of gastroesophageal cancer
Lordick, F., & Janjigian, Y. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.15 · Cited by 161
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
Barok, M., Tanner, M., Köninki, K., & Isola, J. J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.002 · Cited by 160
Grabsch, H. I., Sivakumar, S., Gray, S., Gabbert, H. E., & Müller, W. (2010) · PubMed · doi:10.3233/clo-2009-0497 · Cited by 138
Kim, M. A., Lee, H., Yang, H., Bang, Y., & Kim, W. H. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04012.x · Cited by 135
Kang, Y.-K., Rha, S. Y., Tassone, P., Barriuso, J., Yu, R., Szado, T., Garg, A., & Bang, Y.-J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.356 · Cited by 104
Tegtmeyer, N., Zabler, D., Schmidt, D., Hartig, R., Brandt, S., & Backert, S. (2008) · Cellular Microbiology · doi:10.1111/j.1462-5822.2008.01269.x · Cited by 103
Cho, E. Y., Park, K., Do, I., Cho, J., Kim, J., Lee, J., Kim, S., Kim, K., Sohn, T. S., Kang, W. K., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.205 · Cited by 96
Ahn, S., Ahn, S., Vrancken, M. V., Lee, M., Ha, S. Y., Lee, H., Min, B., Lee, J. H., Kim, J. J., Choi, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5368 · Cited by 67
Recent advances in the HER2 targeted therapy of gastric cancer
Matsuoka, T. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i1.42 · Cited by 52
Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis.
Wang, S., Zheng, G., Chen, L., & Xiong, B. (2011) · PubMed · Cited by 48
Koopman, T., Smits, M. M., Louwen, M., Hage, M., Boot, H., & Imholz, A. L. T. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1900-3 · Cited by 41
Huang, S., Ng, K., Lee, S.-E., Chen, K., Yeh, T., & Chen, T. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0453-0 · Cited by 30
Sitas, F. (2016) · Cancer Epidemiology · doi:10.1016/j.canep.2016.02.002 · Cited by 16
Cited by
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Gastric cancer treatment: recent progress and future perspectives
Guan, W.-L., He, Y., & Xu, R.-H. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01451-3 · Cited by 944
Gastric cancer: a comprehensive review of current and future treatment strategies
Sexton, R. E., Al Hallak, M. N., Diab, M., & Azmi, A. S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09925-3 · Cited by 772
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Targeted Therapies in Advanced Gastric Cancer
Patel, T. H., & Cecchini, M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00774-4 · Cited by 282
Metadata
- Authors
- Abrahao-Machado, L. F., & Scapulatempo-Neto, C.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2016
- Volume
- 22
- Issue
- 19
- Pages
- 4619
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2466335605
- Cited by
- 310
- References
- 30
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.